1. Home
  2. NEN vs ALLO Comparison

NEN vs ALLO Comparison

Compare NEN & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

NEN

New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

HOLD

Current Price

$65.01

Market Cap

227.9M

Sector

Real Estate

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.76

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEN
ALLO
Founded
1977
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
227.9M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NEN
ALLO
Price
$65.01
$1.76
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$8.27
AVG Volume (30 Days)
1.3K
4.6M
Earning Date
03-12-2026
03-12-2026
Dividend Yield
7.38%
N/A
EPS Growth
N/A
N/A
EPS
3.33
N/A
Revenue
$87,362,592.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.54
N/A
Revenue Growth
7.63
N/A
52 Week Low
$62.10
$0.86
52 Week High
$84.00
$3.78

Technical Indicators

Market Signals
Indicator
NEN
ALLO
Relative Strength Index (RSI) 47.46 65.30
Support Level $62.41 $1.54
Resistance Level $65.30 $1.88
Average True Range (ATR) 0.65 0.12
MACD 0.26 0.02
Stochastic Oscillator 64.61 78.07

Price Performance

Historical Comparison
NEN
ALLO

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: